Antioxidants and atherosclerosis. A current assessment.

This publication has 40 references indexed in Scilit:

• Evidence for an additional intracellular site of action of probucol in the prevention of oxidative modification of low density lipoprotein. Use of a new water-soluble probucol derivative.
  Journal of Clinical Investigation, 1992
• Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man.
  Journal of Clinical Investigation, 1989
• Mechanisms of HDL reduction after probucol. Changes in HDL subfractions and increased reverse cholesteryl ester transfer.
  Arteriosclerosis: An Official Journal of the American Heart Association, Inc., 1989
• Probucol does not affect lipoprotein metabolism in macrophages of Watanabe heritable hyperlipidemic rabbits.
  Arteriosclerosis: An Official Journal of the American Heart Association, Inc., 1989
• Beyond Cholesterol
  New England Journal of Medicine, 1989
• Lack of effect of probucol on atheroma formation in cholesterol-fed rabbits kept at comparable plasma cholesterol levels
  Atherosclerosis, 1989
• Development of femoral atherosclerosis in hypercholesterolemic patients during treatment with cholestyramine and probucol/placebo: Probucol quantitative regression Swedish trial (PQRST): A status report
  The American Journal of Cardiology, 1988
• Effects of probucol on xanthomata regression in familial hypercholesterolemia
  The American Journal of Cardiology, 1986
• The Pathogenesis of Atherosclerosis — An Update
  New England Journal of Medicine, 1986
• Altered Metabolism (In Vivo and In Vitro) of Plasma Lipoproteins after Selective Chemical Modification of Lysine Residues of the Apoproteins
  Journal of Clinical Investigation, 1979